跳至主要内容
临床试验/ACTRN12615000106538
ACTRN12615000106538尚未招募未知

Efficacy and safety of artemisinin-based combination therapy: artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the treatment of uncomplicated falciparum malaria in 4 provinces of Burundi

Ministry of Public Health0 个研究点目标入组 528 人开始时间: 2015年2月5日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
528

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
6 Months 至 10 Years(—)
性别
All

入选标准

  • children aged 6 months to 10 years
  • monoinfection with P falciparum confirmed by microscopy
  • parasitemia between 1000-200000 parasites (asexual) per microliter
  • fever (equal or greater than 37.5 celsius) or history of fever within past 24 hours
  • able to swallow oral medication
  • ability and willingness to follow protocol procedures and schedule of assessments
  • written informed consent from parent or guardian

排除标准

  • presence of danger and signs of severe malaria
  • mixed infection or infection of than P. falciparum detected by microscopy
  • severely malnourished
  • fever due to other diseases (measles, acute lower respiratory tract infection, severa diarrhea); chronic or severe hepatic, renal or cardiac diseases; HIV/AIDS
  • clinical signs of acute jaundice
  • abnormal level of granulocytes or liver transaminases
  • regular medication that could interfere with antimalarial pharmacokinetics;
  • history of hypersensitivity reactions or contraindications to any medicines being used

研究者

相似试验